A continuing medical education and nursing continuing professional development activity provided by NAMCP and AAMCN.
This activity is an archive from the live session from the 2025 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.
This activity is valid from August 1, 2025 to August 1, 2026
Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the evaluation and post test. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete it. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate. To print or save your certificate, you will need to click on the "download" button after completing the post test.
Audience: This activity is intended for healthcare professionals practicing in managed care environments.
This activity is supported by educational grants from
Boehringer Ingelheim Pharmaceuticals, Inc. and Bristol Myers Squibb
Description:
Schizophrenia is a complex and chronic psychiatric disorder distinguished by disturbances in thought, cognition, and behavior. It may result in a mix of hallucinations, delusions, and disorganized thinking and behavior. Hallucinations involve seeing things or hearing voices that aren't observed by others. Delusions involve firm beliefs about things that are not true. People with schizophrenia can seem to lose touch with reality, which can make daily living very hard. Disparities persist, and low response rates to the current treatments are poor, with research showing only half of patients being able to live a normal life. It is estimated to impact approximately 2.8 million people in the United States. Symptoms typically first appear in early adulthood and present differently in each person, making symptoms difficult to diagnose and manage.
Fortunately for patients with schizophrenia, new classes of therapy have recently become available for the first time in decades, giving managed care professionals and clinicians new options and approaches for treating this patient population. These new therapies, including muscarinic agonists, offer novel ways to improve patient adherence, functioning and management, and reduce the economic impact associated with nonadherence and relapse. With new therapies entering the treatment paradigm, knowledge gaps have been created, making it imperative that managed care physician medical directors, mental health professionals, pharmacists, payers, nurses and other healthcare professionals who manage schizophrenia patient populations have a solid understanding of these options to optimize both costs and patient outcomes in their therapeutic application, for optimized clinical and economic outcomes.
Upon completion of this activity, participants will be able to:
Faculty:
Joshua Kantrowitz, MD
Associate Professor of Clinical Psychiatry
Columbia University Irving Medical Center
Director, Columbia Schizophrenia Research Center
New York State Psychiatric Institute
Disclosure Information:
As accredited providers, NAMCP and AAMCN must ensure balance, independence, objectivity, and scientific rigor in all of their activities. All faculty participating in this activity are required to disclose to NAMCP/AAMCN any financial relationships with ineligible companies. NAMCP/AAMCN in turn discloses all relevant financial conflicts to the learners. NAMCP/AAMCN disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All relevant conflicts of interest have been mitigated prior to the commencement of the activity. See below for conflicts of interest.
Disclosures (Relevant Financial Relationships with Ineligible Companies in the Last 24 Months):
Dr. Kantrowitz has served as a consultant for Alphasights, Antheum, Bluestar BioAdvisors, Clarivate, ECRI Institute, ExpertConnect, FCB Health, Keyquest health, and Third Bridge. He has served on an advisory board for Leal and Merck. He has received grant/research support from Alkermes, Alto, Boehringer Ingelheim, Click, Neurocrine, Taisho, and Sunovion. He owns individual stock in GSK. All relevant financial relationships have been mitigated.
Planning Committee Disclosures (Relevant Financial Relationships with Ineligible Companies in the Last 24 Months):
Bill Williams, MD has no relevant financial relationship with an ineligible company to disclose.
Jeremy Williams has no relevant financial relationship with an ineligible company to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationship with an ineligible company to disclose.
NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.
Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each physician should claim credit commensurate with the extent of their participation in the activity.
The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.
NAMCP and/or this website do not provide medical advice, diagnosis, or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health-related concern, consult with your physician or healthcare professional.
This activity is supported by educational grants from
Boehringer Ingelheim Pharmaceuticals, Inc. and Bristol Myers Squibb
NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.